Announced, August 2022
Exclusive Licence and Supply Agreement
ATGCKorea
withRELIFEMenarini Group
- Product
- ATGC-100, a novel botulinum toxin type A for medical aesthetics
- Territory
- Europe and the United Kingdom
Business Development and Licensing
The Right European Partner for Your Product. Found. Signed. Launched.
Nosamplio is a UK licensing consultancy for pharmaceutical, medical device and consumer health companies in Korea, Taiwan, China and Japan. We find the licensee or distributor that can take your product to market in Europe, MENA or the Americas, negotiate the deal and support the launch.
Or email us at we@nosamplio.com
Two Recent Agreements
Announced, December 2024
Exclusive Distribution Agreement
SinocareChina
withA. Menarini DiagnosticsMenarini Group
- Product
- iCan continuous glucose monitoring system
- Territory
- More than 20 European jurisdictions
Two Asian innovators. Two exclusive European agreements with Menarini Group companies. Nosamplio supported both.
Rx and Private-Pay Specialists
- Medicines
- Injectables
- Medical Devices
- Aesthetics Devices
- Cosmetics
- Botanicals
- Nutraceuticals
Europe Is Many Markets. The Right Partner Makes It One.
Every European country has its own buyers, prices and reimbursement rules, and many have their own regulator. A strong partner already has the registration team, the sales force and the relationships to reach patients in all of them.
Choosing that partner is the biggest commercial decision you will make for Europe. We help you make it, then we help you make it work.
-
Pharmaceutical and Medical Device
We have supported human health brands across medicines, injectables, medical devices, aesthetics devices, cosmetics, botanicals and nutraceuticals, on prescription and private-pay markets.
-
Strategic Marketing
Professional insight for human health projects: strategic planning, market access, patient access, launch, re-launch and mature commercial strategies.
-
Global Expertise
Sector expertise helping Korean, Taiwanese, Chinese and Japanese companies reach their target audience in Europe, MENA and the Americas.
How We Work
How a Deal Comes Together
Five stages, from the first assessment to a product on the market. You can bring us in at any of them.
Stage 1: Assess the Opportunity
We test your product against the European market: the competition, the likely price and reimbursement, the regulatory route and the size of the prize.
You GetA clear view of where your product fits and who would want it.
Stage 2: Build the Case
We turn your data into the story a partner needs: positioning, a forecast and a non-confidential profile that makes the first meeting count.
You GetPartner-ready materials and a forecast you can defend.
Stage 3: Find and Approach Partners
We shortlist licensees and distributors with the capability, the coverage and the appetite for your product, and open the conversations.
You GetIntroductions to partners who fit your product, not cold lists.
Stage 4: Negotiate the Deal
We help you agree the terms that matter, from exclusivity and territory to milestones, supply and minimum commitments, through to signature.
You GetAn exclusive agreement that works for both sides.
Stage 5: Launch and Grow
After the signature we stay on: market access, marketing, advocacy and sales support, as we do for Sinocare’s iCan in Europe.
You GetA partner that performs, with us watching the launch.
Partner Readiness Check
Is Your Product Ready for a European Partner?
Five quick questions. You will see the deal route that usually fits, what partners will ask you for first and where we would start. Nothing is sent unless you choose to send it.
Your Likely Route
Answer the First Two Questions
Tell us what you are taking to market and where it is today, and the route that usually fits will appear here.
What Partners Will Ask for First
0 of 5 Ready
- Tick what you already have in question five.
Where We Would Start
With a short call about your product and your goals for Europe.
General guidance only, based on how European licensing and distribution deals are usually structured.
Track Record
Deals We Have Supported
Signed agreements and licensing mandates for Korean and Chinese innovators. The signed deals link to their public announcements.
Announced, August 2022
Exclusive Out-Licensing
A Korean Botulinum Toxin, Licensed for Europe and the UK
ATGC Co., Ltd. with RELIFE S.r.l., Menarini Group
ATGC, a Korean biotechnology company, developed ATGC-100, a novel botulinum toxin type A for medical aesthetics. Its licence and supply agreement gives RELIFE exclusive rights to develop, register, promote, distribute and market ATGC-100 in Europe and the UK.
What Nosamplio DidSpecialist pharmaceutical out-licensing consultancy to secure the exclusive European licensing agreement with RELIFE.
Read Menarini’s Announcement (opens in a new tab)Announced, December 2024
Exclusive Distribution
A Chinese CGM System, Taken Across Europe
Sinocare with A. Menarini Diagnostics
The exclusive agreement brings Sinocare’s continuous glucose monitoring products to more than 20 European jurisdictions under a co-branded label, with A. Menarini Diagnostics registering, promoting, distributing and marketing them in reimbursed markets.
What Nosamplio DidSupported the agreement, and represents Sinocare in Europe for iCan business development, market access, marketing, advocacy and sales.
Read Sinocare’s Announcement (opens in a new tab)Licensing Mandate
Global Business Development and Licensing
Global Licensing Support for Green Cross
GC Wellbeing Green Cross
Business development services for a large-cap Korean pharmaceutical company. Featured: GC Wellbeing’s GCWB204, a candidate treatment for cancer cachexia that has completed a European Phase 2a trial.
What Nosamplio DidGlobal business development and licensing services for Green Cross.
Read the GCWB204 Trial News, in Korean (opens in a new tab)Licensing Mandate
Global Out-Licensing
A Commercial-Stage Gastroenterology Product, Offered to the World
GK Pharm Gunkang Pharmaceuticals
OnePrep 1.38 is an easy-to-drink bowel preparation, taken on the day of a colonoscopy for patient convenience.
What Nosamplio DidGlobal licensing consultancy for GK Pharm.
Visit GK Pharm (opens in a new tab)
After the Deal
The Signature Is the Start
A licence only pays when the product sells. So we keep working after the deal is signed, alongside you and your partner.
- Market access and patient access strategy
- Launch, re-launch and mature commercial strategies
- Marketing, advocacy and sales support
- Social, digital and traditional communications
We represent Sinocare in Europe, supporting iCan business development, market access, marketing, advocacy and sales.
The People at the Table
The Licensing Life Sciences Team
Licensing, medicine, compliance, marketing and business intelligence in one team, so your product is judged from every side a partner will judge it.
Lee Taylor
Founding Principal and Managing Director
Speak to Lee directly about your product and where you want to take it.
+44 7714 777 727
Dr Giuseppe Di Benedetto
Medical and Compliance, MD, PhD
A qualified medical practitioner with extensive country-specific pharmaceutical compliance experience.
Frankie Neal
Strategic Marketing and Forecasting
Extensive European and global pharmaceutical marketing experience, giving clients strategic marketing and forecasting insight.
Philip Tomlinson
Business Development and Licensing
Significant pharmaceutical and medical device partnerships experience, supporting clients’ business development and licensing projects.
Zak Farah
Client Business Development
Experience across pharmaceutical licensing, orphan drugs and life science business intelligence.
Harrison Taylor
Marketing and Communications
In-house social, digital and traditional marketing and communications for Nosamplio’s clients.
FAQ
Questions We Are Often Asked
Something else on your mind? Email we@nosamplio.com and we will answer it.
What Does Nosamplio Do?
We are a UK business development and licensing consultancy for life sciences. We help pharmaceutical, medical device and consumer health companies find partners in Europe, MENA and the Americas, agree licensing and distribution deals, and support the launch.
Which Companies Do You Work With?
Mostly companies in Korea, Taiwan, China and Japan with medicines, injectables, medical devices, aesthetics devices, cosmetics, botanicals or nutraceuticals, for prescription and private-pay markets.
What Is the Difference Between a Licence and a Distribution Agreement?
Under a licence, your partner takes the rights to your product in a territory and usually leads registration and marketing there, paying through some mix of upfront fees, milestones, royalties or a supply price.
Under a distribution agreement, you usually keep the approval, and your partner buys, promotes and sells the product. We help you choose the structure that fits your product and your plans.
When Should We Start Talking to European Partners?
Earlier than most companies expect. Partners plan their portfolios years ahead, and early conversations can shape your regulatory plan and the value of the deal. If you have data you can share, it is a good time to talk.
Do You Only Work on Europe?
No. Our best-known deals are in Europe and the UK, and we also support companies reaching MENA and the Americas.
Can You Help After the Deal Is Signed?
Yes. We support market access, patient access, marketing, advocacy and sales after signature. We represent Sinocare in Europe for its iCan CGM.
Where Are You Based?
Nosamplio is based in Stamford, in the United Kingdom, and works with clients across Asia.
Start a Conversation
Tell Us About Your Product
Share what you are taking to market and where you want to sell it. We will reply by email to arrange a first conversation.
- Emailwe@nosamplio.com
- Office+44 (0)1780 723 800
- Lee Taylor, Mobile+44 7714 777 727
- LinkedInConnect With Lee Taylor (opens in a new tab)
Stamford, United Kingdom
